Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
NCT07645820
This study is recruiting at 10 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Atopic Dermatitis
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 12 to 89 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Castle Biosciences Incorporated
- Last updated on ClinicalTrials.gov
- September 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- U.S. Dermatology Partners · Phoenix, AZ
Maryland · 1
- U.S. Dermatology Partners Rockville · Rockville, MD
Michigan · 1
- Derm Research Institute, PLC · Caledonia, MI
Missouri · 1
- U.S. Dermatology Partners Lee's Summit · Lee's Summit, MO
Nevada · 2
- Advanced Dermatology and Cosmetic Surgery - Henderson · Henderson, NV
- Las Vegas Dermatology · Las Vegas, NV
New Hampshire · 1
- StracSkin, PLLC · Portsmouth, NH
Texas · 1
- Harrison Dermatology · Missouri City, TX
Virginia · 1
- Virginia Clinical Research, Inc · Norfolk, VA
West Virginia · 1
- West Virginia Research Institute · Morgantown, WV
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.